益生菌
炎症性肠病
肠道菌群
微生物学
胃肠道
双歧杆菌
化学
免疫学
医学
生物
细菌
疾病
内科学
乳酸菌
遗传学
作者
Kairuo Wang,Qian Chen,Li Ding,Yefei Zhu,Xinyue Wang,Mengting Zhou,Meiqi Chang,Manman Pei,Yuanyuan Zhang,Yang Zhang,Yu Chen,Huanlong Qin
出处
期刊:Nano Today
[Elsevier]
日期:2023-05-24
卷期号:50: 101876-101876
被引量:9
标识
DOI:10.1016/j.nantod.2023.101876
摘要
Prolonged retention in the intestinal tract has important implications for oral medications; however, it remains highly challenging, especially in inflammatory bowel disease (IBD) therapy. The adhesion of a probiotic bacterium to the host intestinal tract can retard its transit through the gut, enhancing its effectiveness. Inspired by this property, we developed a mucoadhesive probiotic-mediated therapeutic strategy with reactive oxygen species (ROS) scavengers to achieve bioadhesion by modulating intestinal inflammation and microbiota. Bifidobacterium longum (BL), an adhesive oral probiotic, was loaded and integrated with hyaluronic acid-bilirubin nanomedicine (HABN) to produce BL@HABN. Both in vitro and in vivo, BL@HABN adhered to epithelial cells and exhibited a longer residence time to mediate more sustained release of preloaded HABN nanodrugs, to eliminate excessive ROS and protect colonic epithelial cells from ROS-mediated cytotoxicity. In addition, BL@HABN reduced the production of pro-inflammatory cytokines, induced type 2 macrophage (M2) differentiation, and promoted epithelial barrier repair. Importantly, it also restored both richness and diversity of the gut microbiota, markedly augmented the abundance of probiotics, and restrained the detrimental bacterial community. This study expands the clinical exploitation of bacteria as an adhesive carrier and enables oral nanomedicine with increased residence time and microbiota homeostasis.
科研通智能强力驱动
Strongly Powered by AbleSci AI